Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    03769506
Previous Study | Return to List | Next Study

ASP-1929 Photoimmunotherapy (PIT) Study in Recurrent Head/Neck Cancer for Patients Who Have Failed at Least Two Lines of Therapy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03769506
Recruitment Status : Recruiting
First Posted : December 7, 2018
Last Update Posted : April 1, 2021
Sponsor:
Information provided by (Responsible Party):
Rakuten Medical, Inc.

Brief Summary:
A Phase 3, Randomized, Double-Arm, Open-Label, Controlled Trial of ASP-1929 vs Physician's Choice Standard of Care for the Treatment of Locoregional, Recurrent Head and Neck Squamous Cell Carcinoma in Patients Who Have Failed or Progressed On or After at Least Two Lines of Therapy

Condition or disease Intervention/treatment Phase
Head and Neck Cancer Combination Product: ASP-1929 Photoimmunotherapy Drug: Physician's Choice SOC Phase 3

Detailed Description:

The study will have an Experimental Arm and a Control Arm.

Experimental Arm:

Patients may receive repeated ASP-1929 PIT interventions for a period of up to 12 months after randomization until the patient has complete remission, progressive disease that is no longer amendable to study treatment, patient experiences intolerable side effects, or patient discontinues study treatment.

Control Arm:

Patients may be treated with physician's choice SOC until the patient has progressive disease, patient experiences intolerable side effects, or patient discontinues study treatment.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 275 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 3, Randomized, Double-Arm, Open-Label, Controlled Trial of ASP-1929 Photoimmunotherapy Versus Physician's Choice Standard of Care for the Treatment of Locoregional, Recurrent Head and Neck Squamous Cell Carcinoma in Patients Who Have Failed or Progressed On or After at Least Two Lines of Therapy, of Which at Least One Line Must Be Systemic Therapy
Actual Study Start Date : May 9, 2019
Estimated Primary Completion Date : September 30, 2024
Estimated Study Completion Date : December 30, 2024

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: ASP-1929 Photoimmunotherapy
Use of ASP1929 PIT therapy
Combination Product: ASP-1929 Photoimmunotherapy
Use of ASP-1929 PIT therapy

Active Comparator: Physician's Choice SOC
docetaxel, cetuximab, methotrexate, paclitaxel
Drug: Physician's Choice SOC
docetaxel, cetuximab, methotrexate, or paclitaxel




Primary Outcome Measures :
  1. Progression-Free Survival [ Time Frame: 24 months ]
    Time to progression of disease

  2. Overall survival [ Time Frame: 24 months ]
    Duration of survival between the two treatment arms



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Overall Inclusion Criteria:

  • Have a histologically confirmed locoregional persistent, recurrent or second primary squamous cell carcinoma of the head and neck, not amenable to curative treatment
  • Have failed or progressed on or after at least 2 lines of therapy for squamous cell carcinoma of the head and neck, one of which must be prior systemic platinum-based chemotherapy
  • Have completed prior curative radiation therapy for treatment of their head and neck region
  • Have locoregional head and neck tumor site(s) that are all accessible to illumination
  • Have target tumors that are clearly measurable by contract enhanced CT scan
  • Have a life expectancy of > 6 months, based on Investigator judgment
  • Male participants must agree to use contraception during the treatment period and for at least 6 months after the last ASP-1929 infusion
  • Female patients of childbearing potential must not be pregnant or breastfeeding and agrees to follow the contraceptive guidance during the treatment period and for at least 6 months after the last dose of trial intervention and must refrain from breastfeeding for at least 2 months after the last ASP-1929 infusion
  • Have an Eastern Cooperative Oncology Group (ECOG) score of 0 or 1

Overall Exclusion Criteria:

  • Have a history of significant (> Grade 3) cetuximab infusion reactions
  • Have been treated with prior systematic chemotherapy or targeted small molecule therapy or radiation therapy within 2 weeks of trial Day 1 or not recovered from adverse events due to a previously administered agent
  • Have been treated with an anticancer monoclonal antibody therapy within 4 of trial Day 1 or have not recovered from adverse events due to previously administered agent
  • Have been treated with an investigational agent or intervention within 4 weeks of trial Day 1 or have not recovered from adverse events, due to previously administered agent or intervention
  • Have a present history of distant metastatic disease (M1)
  • Have an active undergoing treatment or have a diagnosis of an active cancer other than nonmelanoma skin cancer or HNSCC
  • Have a tumor in enhanced CT or MRI scan invading a major blood vessel, unless the vessel has been embolized, stented or surgically ligated to prevent potential bleeding from a blood vessel
  • Have impaired hepatic function
  • Have impaired renal function
  • Have uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with trial requirements
  • Have been previously treated or randomized to any trial using ASP-1929 or RM-1929 PIT as the study treatment

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03769506


Contacts
Layout table for location contacts
Contact: Sumera Raoof, MD, MPH +1 858-925-5619 clinicaltrialinfo@rakuten-med.com

Locations
Show Show 37 study locations
Sponsors and Collaborators
Rakuten Medical, Inc.
Investigators
Layout table for investigator information
Study Director: Sarah Arron, MD Rakuten Medical, Inc.
Publications of Results:
Layout table for additonal information
Responsible Party: Rakuten Medical, Inc.
ClinicalTrials.gov Identifier: NCT03769506    
Other Study ID Numbers: ASP-1929-301
First Posted: December 7, 2018    Key Record Dates
Last Update Posted: April 1, 2021
Last Verified: March 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: Yes
Keywords provided by Rakuten Medical, Inc.:
Rakuten Medical
ASP-1929
PIT
Photoimmunotherapy
HNC
HNSCC
Head and neck
Additional relevant MeSH terms:
Layout table for MeSH terms
Head and Neck Neoplasms
Neoplasms by Site
Neoplasms